Systemic lupus erythematosus is a chronic, multisystem, inflammatory, autoimmune disorder characterized by formation of autoantibodies directed against self-antigens and immune-complex formation.
It can be diagnosed with a single organ involvement such as lupus nephritis.
It is predominantly diagnosed in females of childbearing age.
Clinical presentation varies in different patients and the disease activity varies over time in a single patient. Majority of patients have arthralgia of the hand.
The selective T cell costimulation modulator abatacept drives a rapid improvement in proteinuria, which leads to earlier, sustained complete response compared with placebo in patients with active class III or IV lupus nephritis, although the rate of complete response is similar between groups, suggests a study presented at the EULAR 2018 Congress.
Roshini Claire Anthony speaks with Dr Annie Law, a consultant at the Department of Rheumatology & Immunology, Singapore General Hospital, on how primary care physicians can help in the management of systemic lupus erythematosus (SLE).
Short- and long-term renal outcomes improve with early renin–angiotensin–aldosterone system (RAAS) blockade with renin–angiotensin system inhibitors (RASI) in systemic lupus erythematosus (SLE) patients with antiphospholipid-associated nephropathy (aPLN), according to a study.
Ofatumumab appears to be effective and well-tolerated in the treatment of patients with long-standing systemic lupus erythematosus, offering an alternative to the B cell–depleting agent rituximab, according to a study.
It appears that the Patient Reported Outcomes Measurement Information System Global Health Short Form (PROMIS10), which requires less than 2 minutes to complete, is useable, reliable and can efficiently screen for impaired physical function, emotional distress and pain in outpatients with systemic lupus erythematosus (SLE), reports a study.
Belimumab appears to provide long-term benefits in patients with active systemic lupus erythematosus (SLE), reducing disease activity and prednisone usage while having low accrual of organ damage, according to data from the continuation phase of the multicentre BLISS-76 study from US.
Both the dose and the intensity of longitudinal use of glucocorticoid (GC) are associated with the risk of adverse events (AE) among a nationwide Asian systemic lupus erythematosus (SLE) cohort, according to a recent study.
Treatment with belimumab in Asian patients with systemic lupus erythematosus (SLE) appears to yield significant improvements in disease activity, with a corticosteroid-sparing effect and no new safety signals emerging, according to the results of a phase III trial.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.